Oncocyte Corp·4

Jan 19, 5:14 PM ET

John Anish M. 4

4 · Oncocyte Corp · Filed Jan 19, 2023

Insider Transaction Report

Form 4
Period: 2023-01-17
John Anish M.
SVP, Finance, and Interim CFO
Transactions
  • Award

    Option to Purchase Common Stock

    2023-01-17+250,466250,466 total
    Exercise: $0.46Exp: 2033-01-17Common Stock (250,466 underlying)
Footnotes (1)
  • [F1]The options will become exercisable in three equal installments on each of January 17, 2024, January 17, 2025 and January 17, 2026, subject to continuous service through the applicable vesting date.

Documents

1 file
  • 4
    ownership.xmlPrimary